Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2001

View Archived Issues

Combretastatin significantly potentiates the antitumor action of radioimmunotherapy

Phase II study of AC-2993 shows positive results for type 2 diabetes

Nicox's NCX-1000 protects against portal hypertension in preclinical study

ETA receptor antagonist attenuates angiotensin II- and noradrenaline-induced vasoconstriction

EGFR and HER-2 tyrosine kinase inhibitors with in vivo antitumor activity reported

Progesterone antagonists may provide a new option to suppress menstruation

Agreement to commercialize Anogesic announced by Cellegy and Ventiv

Addition of ZD-1839 to conventional maintenance therapy being evaluated in NSCLC patients

Abgenix and Agensys sign cancer immunotherapy collaboration

Long-term results emphasize Pravachol's good safety profile

Xenova and QLT sign licensing agreement for XR-9576

Atrix and HGSI to develop drug using Atrigel delivery system

Cognetix secures financing to further advance research and discovery efforts

Serono's Saizen approved in E.U. for treatment of adult growth hormone deficiency

Alliance Pharmaceutical submits documentation to the FDA regarding Imavist approval

Allergan's Botox approved for hyperhidrosis in the U.K.

FDA issues approvable letter for Arixtra

FDA approves labeling change for Pfizer's Zoloft

Compounds for delivery of biologically or chemically active agents designed at Emisphere

Kyoto Pharmaceuticals reports carbapenems active against respiratory and urinary tract infections

Novel MMP inhibitors disclosed by Aventis

Aventis develops a new series of Na+/H+ exchange inhibitors

FDA advisory committee recommends approval of Kineret for treatment of RA

Two series of glycogen synthase kinase 3 inhibitors patented by Chiron

Zometa approved by FDA for treatment of hypercalcemia of malignancy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...